News | Telecardiology | May 15, 2020

Telemedicine-based Network Offers Remote Guidance to 100 Million STEMI Patients

Study investigators have created a template for reducing disparities in STEMI management between developed and developing countries

The protocol chart for the LATIN STEMI telecardiology program.

The protocol chart for the LATIN STEMI telecardiology program.

The protocol chart for the LATIN STEMI telecardiology program.

May 15, 2020 – A groundbreaking trial recently examined the viability of telemedicine for remote guidance of a population-based ST-segment elevation myocardial infarction (STEMI) program reaching more than 100 million patients. The study, presented as late-breaking science during the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Virtual Conference

The study helps further prove that telecardiology transcends boundaries, enabling millions of patients to have STEMI care access.

Telemedicine allows healthcare professionals to evaluate, diagnose and treat patients at a distance using telecommunications technology. Within the last decade, the approach has seen striking evolution and in the current COVID-19 climate, has become increasingly important to ensure patients have access to the care they need.

During the study, patients were triaged at spokes that included small clinics and primary healthcare centers in remote locations and transferred to hubs with percutaneous coronary intervention (PCI)-capability. The Latin America Telemedicine Network (LATIN) functioned between 2013 to present in four countries – Brazil, Colombia, Mexico and Argentina.

"As Americans see the benefits of telemedicine in the COVID-19 era, the findings of the [LATIN investigation] should be more relevant and noteworthy,” said Sameer Mehta, M.D., lead author and chairman of the Lumen Foundation. “LATIN is the result of dedicated efforts of more than 2,000 healthcare professionals, including about 600 physicians that were involved in this decade old program.”

Almost 900,000 patients presenting at 351 remote locations were triaged through a STEMI network. The program provided an umbrella of AMI protection to more than 100 million patients in Brazil, Colombia, Mexico, and Argentina. Mortality was reduced by 55 percent and the program contributed to saving $291 million. The results from LATIN trial surpass the total accumulated global experience with telemedicine.

The study investigators tested and proved four attributes of telemedicine:
   • Increased access • Increased accuracy.
   • Cost-effectiveness. 
   • Comprehensive, population-based care and delivery of guidelines-based acute myocardial infarction (AMI) management.

The program was created as a hub and spoke model that was used to expand access. Patients presented at remote clinics and primary care centers and were guided through telemedicine to receive thrombolysis, pharmaco-invasive management, or primary PCI. The role of the telemedicine experts was two-fold: urgent and accurate STEMI diagnosis and tele consultation of the entire STEMI process. Time to telemedicine diagnosis (TTD) was 3.5 minutes and it was possible from tremendous investment in IT infrastructure, with use of cloud computing, business intelligence tools and with GPS navigation. LATIN established TTD as a novel metric of telemedicine efficiency.

“LATIN has established the role of telemedicine in cost-effective and population-based management of AMI that reduces disparities of AMI care between developed and developing countries,” said Mehta. “It has provided a template that can be most beneficial for poorer regions on the world, including in sub-Saharan Africa, the Middle East and in southeast Asia. LATIN can also serve as a model of providing population-based coverage for other systems guided entities such as stroke."

Find links to the rest of the SCAI late-breaking trials and other SCAI news

 

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme